7/26/13

4 Best Biopharma Stock Trades 2013

Below are some of the best trades in the Biopharma Stock Sector since January 2013. I have gathered my research from a pretty good stock investment forum, 4-Trader.  It's all free.  I would never ask you to pay for anything on my site.  No catches, no gimmicks.

If you want to search for other Sectors or other Countries, you can check them out here:

4-Trader.com Stock Sector Research

4-Trader.com Healthcare Sector:  Biotech and Pharmaceutical 

These are highly potential  breakout stocks that I have researched and just posting their results and how to learn more about these Top Stocks in the Healthcare Sector.  More Specifically Biotech and Pharmaceutical Stocks that I predict will be doing very well in the next year with the stock market doing well and the Obamacare being implemented in 2014.  There were a lot to choose from so I pick the best ones that I thought had potential for further gains.

Make Money Off Obamacare

As bad as Obamacare is for business, I think it will improve the Healthcare Sector in the upcoming year and these are all good stocks that I would recommend.  But you can perform your own due diligence yourself, this are the ones that stuck out to me.

Top 4 Biopharma Trades

These are the all the best trades since January, most are above 50% in stock share growth.  Most have higher potentials for further earnings.  These are my own personal 4 picks that I thought were the best of the bunch.

Santarus Inc. (SNTS)

6/7/13

Antares Pharma: $ATRS A Risky Buy That Might Actually Pay Off

Antares Pharmaceuticals is a Hot Biopharma Investment Right Now

Antares Pharma
 
I'm getting back into action here with BioPharma Investor. There is a lot of work I need to do to fix this website and upgrade it as it should be better, but on that note...

So let's start off with Antares Pharma. Most of my previous stocks that I have written about have done very well in the past few years so I'll continue with that trend with this stock: ATRS.

ATRS FDA Approval PDUFA Date is Oct. 14th

     Antares Pharma is a nice play that is gaining a lot of attention this summer with their upcoming PDUFA Date Oct. 14th. This means a nice summer runup for October. With all the hype and partnerships with TEVA and Pfizer buyout talks it seems like a good buy at around $4 a share that it sits as of today.

     If you are new to the investing world and looking for a nice Biorunup, this is probably a pretty good bet. With that being said, I really hope to get back into writing for BioPharma Investor and showing a clear and concise Due Diligence of the stock and why it's a buy or sell.

Here's a few web links to help you out on Antares and what they are all about. 

This is what that blogger from Seeking Alpha, Scott Matusow has to say about Antares.  I agree with a commenter that a buyout would be a couple of years down the road.

Antares Pharma (ATRS)

Antares Pharma

I continue to hear buzz that Antares could be acquired sometime before the end of this year.

Pfizer is the best candidate to buy Antares as both companies already have a working relationship in the form of a "secret deal" that I speculate is an Advil gel based formulation. Company CEO Paul Wotton mentioned last year that Pfizer came to Antares to inquire about one of Antares products, but company Vice President Jack Howarth said that Antares sought out Pfizer for the same deal. Someone is obviously "mistaken" here. I first heard the buyout rumors surrounding Antares in December of 2011, well before the company "appointed" Jack Howarth as a Vice President. Jack is not an official "insider" at Antares, yet has informed some Antares investors that he holds over 400,000 shares of the company. So who does Jack work for? Jack's last official job was with King Pharma, a company Pfizer acquired a few years ago.

The main reason I believe Pfizer will acquire Antares is for its patent profile it holds in regards to biosimilars.

Biosimilars/biobetters, or follow-on biologics, are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product (biosimilars being "similar," biobetters being "better").

Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, the exact fermentation and purification process, or to the active drug substance.

In other words, companies do not need to wait for patent expiration of a biologic to get its hands on the formulation. In fact, because biosimilars/biobetters do not use the exact composition of the biologic drug it is "following after," it is not considered a "copy," therefore, it is not a generic, but a new composition capable of its own unique patent protection. Many large pharmas are gearing up for what I believe to be the wave of the future in biopharmas - biosimilars and biobetters.

Antares has been locking down patents for the past few years with biosimilars, and many speculate the company has a raft-load of these patents secured. Since biosimilars are likely to be the future of biopharma, Antares has placed itself as a strong acquisition target, and as mentioned, I believe Pfizer will be the buyer.

Also, starting in June, there will be warrant expiration occurring. Last year I predicted that Antares would see a pop in its stock price to over $5 a share when the stock was selling for around $3. I based my prediction primarily on the fact of warrant expiration at the time.

I am predicting a similar occurrence this year, and expect a price approaching $5 by the middle of this summer.

Buy out price target opinion: between $7 to $10 a share.



4/16/12

Biopharma Investor

We are working on creating a new full feature design for BioPharma Investor here soon.  Hopefully a better website and more updated content.  Thanks for your patience while I get this up and running.  Web Design and Database Programming doesn't happen overnight.

7/8/11

60 Minutes on J. Craig Venter: Designing Life

J. Craig VenterImage via WikipediaJ. Craig Venter: Designing Life
June 12, 2011 5:00 PM

Steve Kroft profiles famous microbiologist J. Craig Venter, whose scientists have already mapped the human genome and created what he calls "the first synthetic species."

(CBS News) 
This story was first published on Nov. 21, 2010. It was updated on June 12, 2011.
For generations, scientists have wrestled with the idea of creating new forms of life in the laboratory. Now that age is upon us.

Watch the Segment »

6/30/11

Cancer Clinical Trials and Treatments Late Stage Developments

Six bottles of chemotherapeutic agents for inj...Image via WikipediaFrom FierceBiotech

For the cancer drug research enthusiast, this report might read in places like a special oncology edition of a gun magazine. Indeed, there are plenty of weapons against cancer to read about here. Several of the drugs listed here represent the advancement of relatively new methods of attacking cancer, including "armed antibodies" and cancer-killing viruses.

 In addition, decades of basic research into the molecular drivers of cancer growth are bearing fruit for drug developers. Not only are these companies making progress in clinical trials, they have landed buyout deals and lucrative partnerships. It's also clear that relatively small companies like Aveo Pharmaceuticals and Curis are making inroads along side the big boys like Pfizer and Roche.

There are 10 late-stage drugs listed in this report, but this editor hesitates to call them the "Top 10" only because there are so many variables to consider to rank them in such a way objectively. Yet these 10 drugs have certainly been generating news and, in most cases, lots of interest among investors and the medical community. All of the drugs have reached pivotal trials for at least one type of cancer.
Here's the list in alphabetical order by each drug's most commonly used moniker, whether that is its alphanumeric code name or generic name. As always, please let us know whether you think there are cancer drugs in pivotal trials that you think should have been on this list or ones on this list that shouldn't be.

1. Carfilzomib - multiple myeloma
2. Crizotinib (PF-02341066) - lung cancer
3. GDC-0449 (vismodegib) - basal cell carcinoma
4. OncoVex - advanced melanoma
5. PLX4032 (RG7204) - melanoma
6. Ponatinib - leukemia
7. SGN-35 (brentuximab vedotin) - Hodgkin's lymphoma, anaplastic large cell lymphomas
8. Tivozanib (AV-951) - advanced renal cell carcinoma
9. T-DM1 (Trastuzumab-DM1) - breast cancer
10. XL184 (cabozantinib) -  prostate cancer

6/28/11

Killer E. coli Strain Identified in German Outbreak Through Genomic Sequencing: Life Technologies

These are e Coli.Image via WikipediaAs of June 15, the number of people who were ill due to the outbreak of a new E. coli strain in Europe had reached 3,244, according to the Associated Press (AP). Most of the reports have been in Germany, and 784 of the total had developed a serious complication that could lead to kidney failure. AP reported that 37 people have died in Germany, and one person died in Sweden.

The German government has said that it could be a while before the outbreak could be tracked to its ultimate source. Critics have lost no time carping about the way the crisis has been handled.

While the epidemiology has been cumbersome, the genomic sequencing that characterized the pathogen wasn’t. It took all of three days for teams at the University Medical Centre Hamburg-Eppendorf and BGI (formerly known as Beijing Institute of Genomics) to complete the sequence. The research groups used Life Technologies’ Ion Personal Genome Machine (PGM). Simultaneously, University Hospital of Muenster in Germany and Life Technologies confirmed these results.

SOURCE: http://www.lbl.gov/Publications/Curren...Image via Wikipedia

Information Uncovered by Sequencing

“Bioinformatics analysis revealed that this E. coli is a new strain of bacteria that is highly infectious and toxic,” BGI said in its report, issued on June 2. The bacterium is an enterohemorrhagic E. coli (EHEC) serotype O104 strain, which has never been involved in any E. coli outbreaks before, the institute explained.
Described as super-toxic, the strain has 93% sequence similarity with the enteroaggregative E. coli (EAEC) 55989 strain isolated in the Central African Republic and known for causing serious diarrhea. Furthermore, the scientists reported, it has “acquired specific sequences that appear to be similar to those involved in the pathogenicity of hemorrhagic colitis and hemolytic-uremic syndrome.”
Model of successive binary fission in E. coliImage via Wikipedia
The bacteria also produce extended-spectrum beta-lactamases, enzymes that confer resistance to most beta-lactam antibiotics including penicillins, cephalosporins, and the monobactam aztreonam.
University Hospital of Muenster and Life Technologies further noted that “the bacterium at the root of the deadly outbreak in Germany is a new hybrid type of pathogenic E. coli strain.” Their data reportedly showed the presence of genes typically found in two different types of E. coli: EAEC and EHEC.

The Instrument that Did the Sequencing

The Ion PGM chip-based sequencing technology connects chemical and digital information through the use of semiconductor technology. It uses a parallel array of semiconductor sensors to perform real-time measurement of the hydrogen ions produced during DNA replication.

A high-density array of wells on the ion semiconductor chips provides millions of individual reactors, while integrated fluidics allows reagents to flow over the sensor array. The combination, Life Technologies says, enables the direct translation of genetic information to digital information.
 A close-up of E. Coli 1057:H7Image via Wikipedia
“What’s different about it is that it doesn’t use cameras or lasers,” Life Technologies CEO Mark Stevenson told GEN. “We measure the pH change in each well with a semiconductor chip.”

The E. coli crisis in Germany appears to have provided the proof of principle and a field test with highly visible results for the Ion PGM. Life Technologies acquired the technology when it bought Ion Torrent in 2010 for $375 million in cash and stock. Life Technologies began selling the instrument to the marketplace for less than $100,000, calling it an “easy-to-use, highly accurate benchtop instrument optimal for mid-scale sequencing projects such as targeted and microbial sequencing.”

When Ion Torrent introduced the technology in 2007, it expected the innovation to democratize research, enabling every lab to have a sequencer on its bench. At the time, the company said it had planned to sell the machine for $50,000 apiece—about one-tenth the cost of existing instruments. Ion said that the instrument could perform a single sequencing “run” for about $500 in one hour.

Low-temperature electron micrograph of a clust...Image via Wikipedia

Detection in Food

The availability of new technologies has indeed greatly facilitated the genomic sequencing of this potentially lethal bacterium. Life Technologies has also developed a tool to test foods thought to be associated with the outbreak.

On June 6, shortly after reporting results from its sequencing efforts, the firm reported that it had completed development of a custom assay to detect the bacterium. Shipments of the TaqMan® E. coli O104 detection kit are now in Europe.

“A qPCR-based assay test is the most accurate method to detect harmful food-borne pathogens because a positive result indicates the presence of that particular strain’s DNA in the food sample that is being tested,” explained Nir Nimrodi, head of food safety at Life Technologies.
 Escherichia coli on Macconkey Agar PlateImage via Wikipedia
“It is also the fastest. While traditional laboratory testing methods can take up to 10 days for results, this test can determine the presence or absence of the European pathogen in 10 to 24 hours, depending on the sample type and size.”

It is hoped that the TaqMan E. coli O104 detection kits will provide an answer to the question that has received a variety of answers since the initial E. coli outbreak: Where did it come from? Originally, on May 26, health officials pointed to E. coli-contaminated cucumbers from Spain as culprits, but researchers later concluded that the cucumbers were contaminated with a different strain.

Suspicion then moved to bean sprouts but faded away after it was found that 23 of 40 samples from the suspect farm tested negative. As of June 8, focus had shifted back to cucumbers, as a CUCO (cucumber of unknown country origin) that had sickened a family in eastern Germany was found to be contaminated with the outbreak strain. The cucumber was discovered in the family’s compost, but there is no conclusive evidence that it’s the source.

Then on June 10, Reinhard Burger, president of the Robert Koch Institute, said that even though no tests of the sprouts from the suspect farm had come back positive for the E. coli strain behind the outbreak, an investigation into the pattern of the outbreak had produced enough evidence to indict the sprouts. German authorities said that they haven’t yet been able to resolve how sprouts at a farm became contaminated.
Along the search for clues about the source of the killer E. coli food bug, a restaurant in the northern German town of Luebeck and a festival in the northern city of Hamburg have also come under suspicion. The European Union has sent food safety experts to Germany to help authorities there identify the source of the deadly E. coli epidemic.

Stevenson noted that “a concern for the global healthcare industry is the ability to identify these pathogens as they arise and then be able to detect and screen for them rapidly and inexpensively.” Like with the Ion PGM, as novel pathogens continue to emerge, so will the need for similar disruptive but relatively affordable technologies.
Escherichia coli in Endo's agarImage via Wikipedia

Isocitrate Dehydrogenase of Escherichia coli. ...Image via Wikipedia

Enhanced by Zemanta

Anacor Pharmaceuticals and Psoriasis Make Strides With Phase IIb Trials

Treatment ladder for PsoriasisImage via Wikipedia Anacor Pharmaceuticals (NASDAQ:ANAC) announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis. The trial enrolled 68 subjects randomized in a 2:1 ratio, AN2728 to vehicle. Subjects treated with AN2728 showed improvement over vehicle at each of the recorded timepoints during the 12-week study period with peak efficacy of 26% occurring after six weeks of treatment with AN2728.